In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Alexion Pharmaceuticals (ALXN), with a price target of $170.00. The company’s shares closed last Monday at $99.58, close to its 52-week low of $92.56.
According to TipRanks.com, Harrison is a 4-star analyst with an average return of 4.3% and a 53.5% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Global Blood Therapeutics, and Fulcrum Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alexion Pharmaceuticals with a $162.60 average price target, implying a 64.0% upside from current levels. In a report issued on September 26, William Blair also initiated coverage with a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Alexion Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $460 million. In comparison, last year the company had a net profit of $331 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P.
